ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,843 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryCointrinMMV MEDICINES FOR MALARIA VENTURE
MMV MEDICINES FOR MALARIA VENTURE Logo
Verified· 3 sources

MMV MEDICINES FOR MALARIA VENTURE

Summary

About the company

The core activity of the company "Medicines for Malaria Venture" (MMV) is the development, research and provision of medicines to combat malaria, particularly in the areas of: * Development of new antimalarial medicines * Conducting clinical trials and research collaborations * Strengthening local research infrastructure and clinical trial capacity * Providing medicines for vulnerable populations, such as children and pregnant women * Promoting partnerships with local organizations and governments to combat malaria. The company focuses on developing medicines tailored to the needs of people in malaria-endemic regions and works to improve the availability and accessibility of these medicines.

AI-generated
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered11
Discovery, development and provision of antimalarial medicines
Discovery, development and provision of accessible and affordable antimalarial medicines for treatment, prevention and elimination of malaria; from molecule screening and clinical trials to registration and implementation studies.
Research and development for malaria medicines
Research and development for malaria medicines with molecule screening, preclinical studies, clinical trials, approval and post-approval studies; focus on simpler tools, new mechanisms of action and target groups such as children and pregnant women.
Access to malaria medicines
Access to malaria medicines through product registration, regulatory harmonisation, market and behavioural research, training materials, demand planning, and support for financing and supply chains.
Partnerships and calls for proposals
Partnerships under the product development partnership model, calls for proposals, equitable partnerships with malaria-endemic countries, global research networks and partner mapping.
Equitable partnerships in pharmaceutical research
Equitable partnerships for local co-design of R&D processes, strengthening clinical trial capacity and local research infrastructure in affected countries.
Reviews

Aggregated rating

Aggregated rating
4.1
of 5

Aggregated from 7 reviews across all connected sources

Sources
GGoogle4.17
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Knowledge

No knowledge articles yet

Once MMV MEDICINES FOR MALARIA VENTURE has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

MMV MEDICINES FOR MALARIA VENTURE in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank MMV MEDICINES FOR MALARIA VENTURE by reviews, experience and specialisations.

Is this your company?

Claim the company profile of MMV MEDICINES FOR MALARIA VENTURE to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hier entsteht die Karte
Route de Pré-Bois 20
1216 Cointrin
Opening hours
Mon
08:30 - 17:30
Tue
08:30 - 17:30
Wed
08:30 - 17:30
Thu
08:30 - 17:30
Fri
08:30 - 17:30
Sat
Closed
Sun
Closed

At a glance

Legal form
Foundation
UID
CHE-109.363.610
Founded
1999 · 27 years
Last commercial register change
January 7, 2026
Employees
51 to 100

Similar companies

LP
Labatec Pharma SA
Meyrin
NS
NovImmune SA
Plan-Les-Ouates
GI
Givaudan International SA
Vernier
UF
Union for International Cancer Control (UICC)
Geneva
AS
APTISSEN SA
Plan-Les-Ouates
PS
Pharmex SA
Petit-Lancy
EL
Eli Lilly (Suisse) SA
Vernier
FG
Fondation Givaudan
Vernier